Autopsy report · NCT02508077

FOLFIRI and Panitumumab in Treating Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer

Cause of deathSlow enrollment Automatic label, confidence 0.9, unverified. How labels are made.

“Poor Accrual”

The sponsor’s own words in the registry.

Life of this trial

Registered 7 months before it started.
Ran for about 1 year 7 months before it stopped.
1 participant enrolled.
Results were posted on the registry 11 months after it ended.

Vital statistics

Status: Terminated
Phase: Phase 2
Sponsor: City of Hope Medical Center
Sponsor type: University, hospital or other
Conditions: Recurrent Colorectal Carcinoma; Stage IVA Colorectal Cancer; Stage IVB Colorectal Cancer
Interventions: Fluorouracil; Irinotecan Hydrochloride; Laboratory Biomarker Analysis; Leucovorin Calcium; Panitumumab
Participants: 1
Sites: 4
Countries: United States

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.